Data suggest that thermal biomodulation via radiofrequency improves vaginal lubrication and reduces pain during intercourse for postmenopausal women.
A randomized, controlled clinical trial has demonstrated that nonablative capacitive-resistive monopolar radiofrequency (CRMRF) significantly enhanced sexual function and vaginal health in postmenopausal women experiencing genitourinary syndrome of menopause (GSM).1,2 The research published in Menopause, the journal of The Menopause Society, suggested that this regenerative technology offers a safe and effective nonhormone alternative for managing symptoms that affect approximately half of the postmenopausal population.
Genitourinary syndrome of menopause is characterized by a cluster of symptoms, including vaginal dryness, burning, irritation, and dyspareunia, which often lead to decreased sexual desire, arousal, and satisfaction.² While local estrogen therapy remains a standard treatment, many women are either unable to use hormones or prefer nonhormonal options. Conventional treatments like lubricants and moisturizers often provide only temporary relief without reversing underlying physical changes, leading to increased interest in regenerative therapies such as radiofrequency and lasers.
The CRMRF procedure utilizes the oscillation of intracellular molecules and ions to increase tissue temperature.² Maintaining temperatures between 40°C and 45°C allows for cellular biomodulation and improved tissue elasticity, hydration, and structural remodeling without inducing thermal damage.² To evaluate the efficacy of this technology, researchers conducted a single-blind trial involving 62 participants.1,2
The women were randomly assigned to receive either 6 weekly sessions of CRMRF (n = 32) or a sham treatment (n = 30).¹ Investigators assessed sexual function using the Female Sexual Function Index (FSFI) and vaginal health via the Vaginal Health Index (VHI). Estrogenic status was monitored through vaginal cytology, specifically by calculating proportions of basal, intermediate, and superficial cells. Assessments occurred at baseline, immediately post-treatment, and at a 12-week follow-up.
The intervention group demonstrated significantly greater improvements in both primary metrics compared with the control group.1,2 For the FSFI, mean changes were 5.86 in the treatment group versus 1.33 in the sham group at the post-treatment assessment (P < 0.001).¹ At the 12-week follow-up, the FSFI mean changes were 4.41 versus -0.41 (P = 0.011). The study noted that improvements were particularly significant in the domains of lubrication, orgasm, and pain.²
Vaginal health outcomes showed even more pronounced differences:
Statistical analysis revealed moderate to large effect sizes for the FSFI (Cohen d > 0.77; 95% CI, 0.25-1.29) and large effect sizes for the VHI (d > 3.49; 95% CI, 2.68-4.28).¹ Notably, no significant changes were observed in estrogenic status, and the study reported no adverse events, suggesting the treatment is well-tolerated.¹
The findings contribute to a growing body of evidence indicating that radiofrequency can achieve results comparable to estrogen therapy and superior to moisturizers for certain GSM symptoms. However, this study is distinct for its use of a sham-controlled group to address previous gaps in intracavitary radiofrequency research.²
"This small study provides preliminary evidence on the effectiveness of nonablative radiofrequency on vaginal health and sexual function in postmenopausal women,” said Stephanie Faubion, MD, MBA, FACP, MSCP, IF, medical director for The Menopause Society, in a press release. “Additional studies in larger and more diverse cohorts with multidimensional outcome assessments and longer-term follow-up are needed to confirm clinical applicability.”
The researchers concluded that CRMRF is a safe and effective intervention for improving the quality of life and sexual well-being of postmenopausal women.¹,² While the study was small-scale, the lack of adverse events and the significant improvements in vaginal hydration and sexual satisfaction support the use of radiofrequency as a viable regenerative therapy for those seeking nonhormonal care.1,2
References:
